FORSUNPHARMA Announces Major Strategic Move to Privatize Henlius

On June 24, 2024, FORSUNPHARMA announced a major strategic move in its official announcement, planning to privatize its core innovative assets - Henlius - through an absorption and merger. This decision aims to further strengthen FORSUNPHARMA's strategic layout in the field of innovative biopharmaceuticals and drive the sustainable growth of Henlius.

The cash consideration for this absorption and merger transaction is set at HKD 24.6 per share, which represents a premium of up to 36.67% over the closing price on the unaffected trading day, and a premium of 52.04% over the average price of the 30 trading days prior to the unaffected trading day. Overall, the cash consideration for this absorption and merger is not expected to exceed approximately HKD 5.407 billion, or the equivalent in RMB. This move not only reflects FORSUNPHARMA's high recognition of Henlius, but also demonstrates its firm confidence in the future of the biopharmaceutical industry.

Henlius, as an internationalized innovative biopharmaceutical company, has always been dedicated to providing high-quality and affordable biologics to patients worldwide. Its product pipeline covers a wide range of fields, including oncology, autoimmune diseases, and ophthalmology, with 5 products already launched in the Chinese market and 3 products successfully approved and launched in the international market. Among them, Hanlikang® (rituximab biosimilar) is the first domestically produced biosimilar to be approved and marketed, breaking the monopoly of foreign brands; Hanhang Youm® (trastuzumab biosimilar) has also become the first domestically produced monoclonal antibody biosimilar to be approved in China, Europe, and the United States, demonstrating Henlius' strong capabilities in internationalization.

In the past few years, Henlius has achieved remarkable performance results thanks to its outstanding R&D capabilities and innovative strength. In 2023, the company's revenue reached RMB 5.395 billion, and its net profit even reached RMB 560 million, realizing profitability for the full year. This achievement not only proves Henlius' leading position in the biopharmaceutical field, but also lays a solid foundation for its future development.

As the parent company of Henlius, FORSUNPHARMA is also a globally influential group in the pharmaceutical and healthcare industry. For the past 30 years, FORSUNPHARMA has always adhered to the "patient-centric" philosophy, focusing on technological innovation and unmet clinical needs. The company has established a diversified and multi-level open innovation system centered on independent R&D, collaborative development, licensing, and in-depth incubation, covering core therapeutic areas such as oncology (solid tumors, hematological tumors), autoimmunity, central nervous system, and chronic diseases (liver/metabolism/kidney). By continuously accelerating the R&D and commercialization of innovative technologies and products, FORSUNPHARMA has driven the high-quality development of the company.

In 2023, FORSUNPHARMA's revenue reached RMB 41.4 billion, of which the pharmaceutical business as the core business segment achieved a revenue of RMB 30.222 billion. Among them, key innovative products such as Hanshu® (sintilimab injection), Hanhang Youm® (trastuzumab for injection), and Suoxin® (avapritinib tablets) maintained rapid growth in revenue, further consolidating the company's leading position in the industry.

Through this absorption and merger of Henlius, FORSUNPHARMA will further consolidate its leading position in the field of innovative biologics, accelerating the R&D and commercialization of innovative products. At the same time, this will also provide Henlius with a broader development space and more abundant financial support, helping it achieve even more brilliant performance results. Looking ahead, FORSUNPHARMA will continue to adhere to the "patient-centric" philosophy, continuously promote technological innovation and industrial upgrading, and provide global patients with higher-quality, more efficient, and more affordable pharmaceutical and healthcare services.